Company: INDP
Filing Date: 2025-06-23
Form Type: DEF 14A
Source: 0001641172-25-016071
Chunk: 13

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-06-23
Form: DEF 14A
Chunk 13
---
% of the Conversion Shares if they subscribed after June 30, 2025. The Common Warrants are exercisable on the date which is the
later of (i) the Conversion Date and (ii) the date stockholder approval is obtained and will expire on the five year anniversary thereafter.
The Common Warrants will have an exercise price equal to the Conversion Price.

Paulson Investment Company,
LLC (“Paulson”) served as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to
a Placement Agent Agreement (the “PAA”) between the Company and Paulson. As compensation for such placement agent services,
the Company has agreed to pay Paulson an aggregate cash fee equal to 12.0% of the gross proceeds received by the Company from the Private
Placement, and a non-accountable expense of $25,000. In addition, Paulson is entitled to certain tail rights for a period of one year
following the termination or expiration of the PAA. The Placement Agent will also receive Placement Agent Warrants to purchase a number
of shares of our common stock equal to 12% of the shares of common stock underlying the Notes issued in the Private Placement. The Placement
Agent Warrants will have the same terms as the Common Warrants and will expire on the fifth anniversary of the issue date. The PAA contains
certain customary representations and warranties and indemnification obligations of the Company and Paulson.

<div align='center'>7</div>

Nasdaq Stockholder Approval Requirement; Reasons for the Issuance Proposal

Nasdaq Listing Rule 5635(d) requires
stockholder approval in connection with a transaction, other than a public offering, involving the sale or issuance by the issuer of
common stock (or securities convertible into or exchangeable for common stock) equal to 20% or more of the common stock or 20% or more
of the voting power of such company outstanding before the issuance for a price that is less than the lower of: (i) the closing
price of the common stock immediately preceding the signing of the binding agreement for the issuance of such securities, and (ii) the
average closing price of the common stock for the five trading days immediately preceding the signing of the binding agreement for the
issuance of such securities (such price, the “Nasdaq Minimum Price”).

Because the Conversion Price and exercise price
of the Common Warrants and Placement Agent Warrants may be less than the Nasdaq Minimum Price,